Impedimed is a medical devices company that produces electronic devices capable of measuring the level of fluid in the human body, explains Shane Fitzgerald, Principal at Monash Investors. Their primary product, L-Dex, allows for the early detection of an otherwise incurable condition called Lymphedema, which affects cancer patients after treatment. “What gets us really excited about Impedimed is that it’s not just about Lymphedema, this is a platform business. They can measure body-fluid changes wherever.” One area in which they’re currently developing a new product is the early detection of chronic heart disease, a market many times larger than Lymphedema. Watch the full video to hear why he thinks Impedimed offers a lower risk profile than typical for medical device developers.
Monash was established in 2012 by Simon Shields and Shane Fitzgerald. The Monash strategy is benchmark unaware, style and stock size agnostic, and is both long and short.